Brief: Geneuro's Temelimab Phase 2 Trial Cleared To Continue

Geneuro SA

02/03/2021 06:52

March 2 (Reuters) - GENEURO SA  GNRO.PA :
    * GENEURO’S TEMELIMAB PHASE 2 MULTIPLE SCLEROSIS TRIAL
CLEARED TO
CONTINUE FOLLOWING PLANNED DATA SAFETY MONITORING BOARD MEETING
    * PHASE 2 TOP-LINE RESULTS ON TRACK TO BE REPORTED IN Q1
2022
    * DSMB CONFIRMS HIGHER DOSES OF TEMELIMAB IN PROTECT-MS
PHASE 2
STUDY ARE WELL TOLERATED
    * PATIENT ENROLMENT INTO PROTECT-MS RECENTLY COMPLETED WITH
COHORT
OF 42 PATIENTS BEING TREATED FOR 48 WEEKS WITH TEMELIMAB VERSUs
PLACEBO

Source text for Eikon:  ID:nBwbjLs18a 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))